Emergent BioSolutions (NYSE:EBS) Stock Price Down 3.9% – What’s Next?

Emergent BioSolutions Inc. (NYSE:EBS) was down 3.9% during trading on Tuesday . The company traded as low as $10.78 and last traded at $10.75. Approximately 113,481 shares traded hands during trading, a decline of 89% from the average daily volume of 992,138 shares. The stock had previously closed at $11.19.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on EBS. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Finally, Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Down 2.4 %

The stock’s fifty day moving average is $9.39 and its 200 day moving average is $9.31. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock has a market cap of $591.65 million, a P/E ratio of -2.66 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $293.80 million for the quarter, compared to analyst estimates of $328.72 million. During the same quarter in the prior year, the firm posted ($1.44) EPS. As a group, equities research analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Several institutional investors and hedge funds have recently modified their holdings of the stock. SeaCrest Wealth Management LLC increased its holdings in Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after buying an additional 3,705 shares during the period. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions in the 3rd quarter valued at $96,000. FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the 3rd quarter worth $103,000. Hilltop Holdings Inc. lifted its stake in shares of Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock worth $1,430,000 after purchasing an additional 12,515 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Emergent BioSolutions during the 2nd quarter worth $93,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.